Form 4: Annovis Bio Director Michael Hoffman Boosts Stake with Significant Share Purchase

Annovis Bio, Inc. Director and 10% owner Michael B. Hoffman acquired 5,000 shares of common stock at $2.43 per share, signaling increased insider confidence.

Summary

• Michael B. Hoffman, a Director and 10% owner of Annovis Bio, Inc. (ANVS), acquired 5,000 shares of the company's common stock.
• The transaction took place on May 29, 2025, with shares purchased at a price of $2.43 per share.
• Following this acquisition, Mr. Hoffman directly beneficially owns 1,421,283 shares of common stock.
• Additionally, he indirectly beneficially owns 223,357 shares through The 2018 Jane and Michael Hoffman Descendants Trust, over which he maintains voting and investment power.

Sentiment

Score: 8

Explanation: The acquisition of shares by a director and significant owner is generally viewed as a strong positive signal, indicating management's confidence in the company's prospects and valuation.

Positives

• A key insider, Michael B. Hoffman, who serves as both a Director and a 10% owner, increased his direct stake in Annovis Bio, Inc. by purchasing 5,000 shares, which is often interpreted as a strong vote of confidence in the company's future prospects and current valuation.
• The acquisition was made at a specific price of $2.43 per share, providing a clear indication of the valuation at which a significant insider is willing to invest additional capital.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Michael B. Hoffman indirectly beneficially owns 223,357 shares through The 2018 Jane and Michael Hoffman Descendants Trust, a related party over which he has voting and investment power.

Stakeholder Impact

• Shareholders: The insider purchase may instill confidence among existing shareholders and potentially attract new investors, as it suggests a positive outlook from a key company figure.

Key Dates

Recommendation

Keywords

Annovis Bio, ANVS, Insider Trading, Form 4, Stock Purchase, Director, Beneficial Ownership, Michael B. Hoffman, Biotechnology, Pharmaceuticals